The Effect of Prangos Ferulacea Vaginal Cream on Accelerating the Recovery of Bacterial Vaginosis: A Randomized Controlled Clinical Trial

Asieh Azadpour Motlagh1, MS Student, Mahrokh Dolatian2, PhD; Faraze Mojab3, PhD; Malihe Nasiri4, PhD; Behrouz Ezatpour5, PhD; Yadollah Sahranavard6, MS; Heshmat Shakiba7, BS; Bahram Rahimy8, MS; Kiandokht Ghanati9, PhD candidate

1International Branch of Shahid Beheshti, University of Medical Sciences, Tehran, Iran; 2Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Department of Paramedical, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 5Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Lorestan, Iran; 6Department of Paramedical, School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran; 7Department of Paramedical, Islamic Azad University Borjerd Branch, Borjerd, Iran; 8Department of Nursing and Midwifery, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran; 9National Nutrition and Food Technology Research Institute, Department of the International Affairs of Shahid Beheshti University of Medical Sciences, Tehran, Iran

Corresponding author: Mahrokh Dolatian, PhD; Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Postal code: 19968-35119, Tehran, Iran Tel: +98 21 88202517; Fax: +98 21 88202517; Email: mhdolatian@gmail.com

Received: 6 August 2017 Revised: 4 December 2017 Accepted: 9 December 2017

ABSTRACT

Background: The present study was conducted on the effect of prangos ferulacea vaginal cream on accelerating the recovery of bacterial vaginosis.

Methods: This randomized controlled clinical trial was conducted on 100 non-pregnant women referring to health centers affiliated to Lorestan University of Medical Sciences in 2016 with the diagnosis of bacterial vaginosis based on the patient’s complaints, Amsel’s clinical criteria, and the Nugent microscopic criteria. The women were randomly divided into two groups of 50. One group was treated with oral metronidazole plus Prangos ferulacea vaginal cream and the other with oral metronidazole plus a placebo vaginal cream for seven days. The patient’s complaints, Amsel’s clinical criteria and the Nugent microscopic criteria were assessed seven days after treatment. The data were analyzed using SPSS, version 20, with a significance level of 0.05.

Results: The response to oral metronidazole plus Prangos ferulacea vaginal cream treatment was 94% according to Amsel’s clinical criteria and 88% according to the Nugent microscopic criteria. The response to oral metronidazole plus placebo vaginal cream treatment was 94% according to Amsel’s criteria and 86% according to the Nugent criteria. The analysis of the patients’ complaints, Amsel’s clinical criteria and the Nugent microscopic criteria showed significant differences in each group before and after the treatment.

Conclusion: This trial showed that Prangos ferulacea vaginal cream accelerated the recovery of
bacterial vaginosis of patients with bacterial vaginosis. It can be used effectively as a complementary treatment with oral metronidazole in cases of medication resistance and also in people wishing to use herbal remedies.

**Trial Registration Number:** IRCT2016042327534N1

**Keywords:** Bacterial vaginosis, Complementary alternative medicine, Metronidazole, Therapeutics, Vaginal cream

**Please cite this article as:** Azadpour Motlagh A, Dolutian M, Mojab F, Nasiri M, Ezatpour B, Sahranavard Y, Shakiba H, Rahimy B, Ghanati K. The Effect of Prangos Ferulacea Vaginal Cream on Accelerating the Recovery of Bacterial Vaginosis: A Randomized Controlled Clinical Trial. IJCBNM. 2018;6(2):101-110.

**INTRODUCTION**

Bacterial Vaginosis (BV) is the most common type of vaginitis in women of reproductive age. BV is a change in the normal vaginal flora that leads to the loss of hydrogen peroxide-producing lactobacilli and the overgrowth of predominantly anaerobic bacteria. The normal vaginal flora contains a variety of lactobacillus species that help maintain the acidic pH of the vagina (below 4.5), which is suitable for the production of lactic acid. The classic signs of BV include abnormal discharge and pungent amine odors. The exact cause of disruption in the normal vaginal flora is still unknown, but the frequent alkalinity of the vagina due to frequent intercourse or the use of vaginal douche is identified and accepted contributors.

The known risk factors of this form of vaginitis include socioeconomic status, poor hygiene, early sexual activity, several sexual partners, psychological stress, and biogenetic factors.

Although BV is the most common cause of vaginal discharge with a prevalence of 33% to 47% during pregnancy, it is asymptomatic in 50% of the cases. There is little statistical information on the prevalence of BV in Iran, but it was reported to be 15.6% in Yazd, 16.2% in Zanjan, and 70.34% in infertile women in Qom.

The complications of BV include Pelvic Inflammatory Disease (PID), infertility, endometritis, vaginal cuff cellulitis, urinary tract syndrome and increased susceptibility to sexually transmitted infections (STI) such as HIV.

The recommended treatment for bacterial vaginosis is administration of metronidazole for one week. Oral metronidazole is associated with gastrointestinal and cutaneous rashes as its side-effects and may cause dizziness, seizure, peripheral neuropathy, metallic taste and dry mouth and insomnia or sleepiness after passing through the blood-brain barrier.

Various studies have been conducted on non-pharmaceutical substances that can be replaced with metronidazole. Particular attention is currently being paid to herbal medicines as alternatives to chemical medicines in the treatment of infectious diseases. A herb with antibacterial properties is Prangos ferulacea (Jashir in Persian), which is a traditional Iranian medicinal plant. Prangos ferulacea has a highly fragrant, yellowish, saffron-colored resin that is extracted from the plant’s roots and stems. In traditional medicine, Prangos ferulacea is used for the treatment of joint inflammation vascular occlusion, hemorrhage, vaginal itching and infection, neutralization of toxins, uterine infections, and removal of dead fetus.

In Eastern Anatolia, Prangos ferulacea was used as a food item. The essence of Prangos ferulacea is a secondary plant metabolite that is used in food, pharmaceutical and hygiene industries as an antimicrobial compound. Due to the lack of clinical trials so far, prangos ferulacea is contraindicated in pregnancy.

Given the complications caused by bacterial vaginosis, the microbial resistance developed against chemical medications in recent years, the acceptability of herbal and traditional medicines, the present study was...
Azadpour Motlagh A, Dolatian M, Mojab F, Nasiri M, Ezatpour B, Sahranavard Y, et al. 

conducted to determine the effect of Prangos ferulacea vaginal cream on accelerating the recovery of bacterial vaginosis.

**MATERIALS AND METHODS**

The present triple-blind, randomized, controlled, clinical trial was conducted from late November 2015 to late November 2016 in health centers affiliated to Lorestan University of Medical Sciences. The study subjects included non-pregnant, non-lactating, non-menopausal, married women aged 15 to 49 with complaints of vaginal discharge, with regular menstrual cycles, no other forms of vaginitis, not having used vaginal or antibiotic medications over the last two weeks, not having participated in other studies over the last four weeks, and having no cervical problems/abnormalities or chronic medical diseases; those who were also willing to participate in the study were enrolled after submitting their informed written consents. Also, those who were unwilling to continue cooperation at any stage of the study or forgot to take one of their medication doses, had intercourse, became pregnant, had menstrual bleeding, and did not visit on time were excluded from the study.

The study population consisted of women visiting the aforementioned clinics. 214 people entered the study. 104 people were excluded because of not meeting the inclusion criteria (n=83), lack of willingness to participate (n=15), and other reasons (n=6). Finally, 110 women remained in the study. In each group, 5 women were excluded. (Consort flowchart 1: Figure 1).

A total of 100 women with bacterial vaginosis were selected through convenience purposive sampling and based on Amsel’s criteria, their gram-staining results, and the Nugent microscopic score. Based on random allocation software, the women were then divided into an intervention group (50 women) and a control group (50 women). The presence of three out of the following four Amsel’s criteria confirmed the diagnosis of bacterial vaginosis: (1) Thin, gray, homogeneous discharge; (2) pH>4.5; (3) positive whiff (amine) test; and (4) more than 20% clue cells in the wet mount.18 Gram-staining was then used based on the Nugent

![Figure 1: Consort flow chart](image-url)
scoring system to make the final confirmation (scores 0-3=normal; 4-6 =intermediate; and 7 and higher =definite bacterial vaginosis). Recovery from BV was assumed with only 0 or 1 criterion out of the four Amsel’s criteria and a Nugent score of 0-3.

The data collection tools used in the study included a demographic questionnaire, an observation checklist for pre-post-medication differences considering the patient’s complaints, Amsel’s clinical criteria, the Nugent microscopic criteria and the medication side-effects.

The study was conducted after obtaining the approval of the ethics committee of Shahid Beheshti University of Medical Sciences (ID: IR.SBMU.RETECH.REC.1395.25). For data collection, the researcher visited the study settings, introduced herself, obtained the permission of the directors of the centers, and conducted preliminary interviews with the patients (briefed them on the study objectives and the confidentiality of the data). Eligible candidates were then selected for participation in the study. One of the checklists used in the study inquired about the patients’ demographic and obstetrical history and complaints and the other checklist was about direct observation during the examination; in addition, a vaginal pH measurement, the whiff test and a microscopic observation of the clue cells in the wet mount and the stained slides based on the Nugent scoring system were completed. The patient was placed in a lithotomy position; using a disposable speculum (without lubricant), we assessed her discharge and symptoms through direct observation. If the discharge was uniform, thin and gray and no cervicitis was observed, a specimen was taken from the vaginal sidewalls using a sterile cotton swab. The vaginal discharge was smeared onto a pH indicator strip from one side of the slide to the other. The pH was determined by comparing the color change in the pH indicator strip with the instructions on the box. If pH>4.5, the second swab was prepared and a drop of potassium hydroxide 10% was poured onto it, and the whiff test result was confirmed as positive if the swab took the pungent smell of rotten fish (due to the release of aromatic amines). For the microscopic observation of the wet vaginal discharge at ×40 magnifications, a drop of normal saline was poured onto the slide and an 18×18 slide was placed onto it. Immediately after that, the absence of polymorphonuclear cells, red blood cells (RBC), sperm, trichomoniasis and yeast with the scientific name Pseudomycecla or candiasis, and the observation of clue cells were assessed. If three of the four Amsel’s clinical criteria were positive, the diagnosis of bacterial vaginosis was confirmed and the fourth swab was prepared for the microscopic diagnosis of bacterial vaginosis, smeared onto a slide in the same way, dried at room temperature, and then fixed with an alcohol burner. The slide was then immediately stained in four stages using the gram-staining method. For better clarity, a drop of immersion oil was poured onto the slide and then observed under a photomicroscope at thousand magnifications (×100). Gram-negative diplococci, gram-negative coccobacilli and an abundance of gram-variable bacteria, mobiluncus or clue cells indicated BV based on the Nugent score, and the final diagnosis of BV was confirmed by gram-staining according to the Nugent scoring system. The medication administration self-reporting form was distributed among the patients. The patients had to record their symptoms, full recovery, recurrence of symptoms and medication side-effects on a daily basis over the seven days of the medication administration and the following seven days. Both vaginal creams were prepared by the physicochemical control laboratory of the School of Pharmacy of Shahid Beheshti University of Medical Sciences in aseptic conditions. The Prangos freulecea gum is a 30gr vaginal cream. Each tube has 20 grams of active ingredient. Herbarium number was HSP-102. The Prangos ferulacea was extracted from the Apiaceae species and the genus Prangos genus. The placebo consists of Seto astyaril alcohol, Petroleum...
jelly, Glycerine, Mineral Oil, Antioxidant, and protective materials.

The creams were labeled A and B (the researcher was blinded to their content). Oral metronidazole tablets (250 mg, made by Dr. Abidi Pharmaceutical Company, drug registration NO: 128067198) were purchased and delivered to the researcher. The patients received their Prangos ferulacea or placebo vaginal cream by drawing a card containing the letter A or B from a box (each letter corresponded to one of the treatments and the box contained an equal number of cards labeled A and B). The two groups received similar metronidazole tablets (500-mg, to be administered 12-hourly) while one group received Prangos ferulacea vaginal cream and the other placebo vaginal cream (to use 5 grams every night with an applicator). The patients were asked to return for reassessment a week after completing the course of their treatment, and the same diagnostic method as in their first visit was repeated for them (based on the patient’s complaints, Amsel’s clinical criteria and the Nugent microscopic criteria). The patients were informed of their recovery status immediately after the examination, and those with a negative response underwent another course of treatment.

The data obtained were analyzed in SPSS-20 using descriptive and deductive (independent t-test, the Chi-square test, Fisher’s exact test, Mann-Whitney’s test and McNemar’s test) statistics at a significance level of $P<0.05$.

**RESULTS**

This study examined 110 married women who were randomly divided into two groups of 55 each. Four women were later excluded from the study for late attendance, one for getting pregnant and five others for lack of attendance for follow-up. A total of 100 women (50 per group) with a Mean±SD of 31.96±8.93 years remained in the study. The results showed no significant differences between the two groups in terms of their demographic characteristics (Table 1).

The Chi-square test and Fisher’s exact test performed before the treatment showed no itching, burning or vaginal and vulvar irritation in any of the women in the Prangos ferulacea and metronidazole groups. A total of 97% of the patients in both groups complained about profuse discharge and 94% about bad odor; Table 2 presents these complaints and their changes after the treatment.

According to the examiner, the clinical observation showed no redness or inflammation of the vagina, vulva or cervix in any of the participants in the two groups. Before the treatments, Amsel’s clinical criteria showed that 92% of the participants in both

| Table 1: Comparison of demographic characteristics of participants in the control and intervention groups |
|--------------------------------------------------------------------------------------------------|
| **Variable** | **Intervention group** | **Control Group** | **P value** |
|--------------|------------------------|------------------|-------------|
| **Education** Patient | A primary school& school | 24 (48) | 23 (46) | 0.918 |
| | High school | 4 (8) | 5 (10) |
| | Collegiate | 22 (44) | 22 (44) |
| Husband | A primary school& school | 18 (36) | 13 (26) | 0.232 |
| | High school | 29 (58) | 32 (64) |
| | Collegiate | 3 (6) | 5 (10) |
| **Profession** Patient | Housekeeper | 43 (86) | 40 (80) | 0.221 |
| | Worker | 4 (8) | 9 (18) |
| | Employee | 3 (6) | 1 (2) |
| Husband | Unemployed | 2 (4) | 1 (2) | 0.118 |
| | Worker | 19 (38) | 9 (18) |
| | Employee | 10 (20) | 16 (32) |
| | non-government | 19 (38) | 24 (48) |

*Chi square test
Accelerating the recovery of bacterial vaginosis with prangos ferulacea vaginal cream

Groups had homogeneous gray discharge, 100% had pH>4.5, and 100% had positive amine tests. Two-thirds of the patients in the Prangos ferulacea group and half of those in the metronidazole group at four hundred magnification (×40) had clue cells>20%. Moreover, 100% of the patients at thousand magnifications (×100) had Nugent scores≥7 before the treatment; Table 3 presents these scores and their changes after the treatment.

The analysis of the patients’ complaints, Amsel’s clinical criteria and the Nugent microscopic criteria using McNemar’s test showed significant differences in each group before and after the treatment (Table 4).

On average, the first day when the symptoms subsided over the seven days of the medication administration period was day 3.14±1.01 in the Prangos ferulacea group and day 3.88±0.917 in the metronidazole group.

**Table 2:** Comparison of clinical improvement in patients’ complaints in the control and intervention groups (N=50)

| Variable                  | Intervention group | P value within Intervention Group* | Control Group | P value within Control Group* | P value Between* |
|---------------------------|--------------------|------------------------------------|---------------|-------------------------------|-----------------|
| Patient complaints        |                    |                                    |               |                               |                 |
| Abundant discharge        |                    |                                    |               |                               |                 |
| Before treatment          | Yes                | 49 (98)                            | <0.001        | 48 (96)                       | 1.000           |
|                          | No                 | 1 (2)                              |               | 2 (4)                         |                 |
| After treatment           | Yes                | 8 (16)                             |               | 15 (30)                       | 0.0961          |
|                          | No                 | 42 (84)                            |               | 35 (70)                       |                 |
| Malodor                   |                    |                                    |               |                               |                 |
| Before treatment          | Yes                | 44 (88)                            | <0.001        | 50 (100)                      | 0.0272          |
|                          | No                 | 6 (12)                             |               | 0 (0%)                        |                 |
| After treatment           | Yes                | 0 (0)                              |               | 2 (4)                         | 0.495           |
|                          | No                 | 50 (100)                           |               | 48 (96)                       |                 |

*Chi square test

**Table 3:** Comparison of clinical improvement in Amsel clinical criteria and Microscopic Nugent criteria in the control and intervention groups

| Variable                  | Intervention group | P value within Intervention Group* | Control Group | P value within Control Group* | P value Between* |
|---------------------------|--------------------|------------------------------------|---------------|-------------------------------|-----------------|
| Amsel clinical criteria   |                    |                                    |               |                               |                 |
| Gray homogeneous discharge|                    |                                    |               |                               |                 |
| Before treatment          | Yes                | 46 (92)                            | <0.001        | 46 (92)                       | 1.000           |
|                          | No                 | 4 (8)                              |               | 4 (8)                         |                 |
| After treatment           | Yes                | 3 (6)                              |               | 8 (16)                        | 0.110           |
|                          | No                 | 47 (94)                            |               | 42 (84)                       |                 |
| 4.5≥pH                    |                    |                                    |               |                               |                 |
| Before treatment          | Yes                | 50 (100)                           | <0.001        | 50 (100)                      | 1.000           |
|                          | No                 | 0 (0)                              |               | 0 (0)                         |                 |
| After treatment           | Yes                | 3 (6)                              |               | 6 (12)                        | 0.478           |
|                          | No                 | 47 (94)                            |               | 44 (88)                       |                 |
| Whiff test positive       |                    |                                    |               |                               |                 |
| Before treatment          | Yes                | 50 (100)                           | <0.001        | 50 (100)                      | 1.000           |
|                          | No                 | 0 (0)                              |               | 0 (0)                         |                 |
| After treatment           | Yes                | 5 (10)                             |               | 12 (24)                       | 0.062           |
|                          | No                 | 45 (90)                            |               | 38 (76)                       |                 |
| Clue cells more than 20%  |                    |                                    |               |                               |                 |
| Before treatment          | Yes                | 35 (70)                            | <0.001        | 26 (52)                       | 0.065           |
|                          | No                 | 15 (30)                            |               | 24 (48)                       |                 |
| After treatment           | Yes                | 2 (4)                              |               | 1 (2)                         | 1.000           |
|                          | No                 | 48 (96)                            |               | 49 (98)                       |                 |
| Microscopic criteria      |                    |                                    |               |                               |                 |
| Nuggest                   |                    |                                    |               |                               |                 |
| Before treatment          | Score ≥ 7          | Yes                                | <0.001        | 50 (100)                      | 1.000           |
|                          | Score 0-3          | No                                 |               | 44 (88)                       |                 |
| After treatment           | Score ≥ 7          | Yes                                | <0.001        | 7 (14)                        | 0.766           |
|                          | Score 0-3          | No                                 |               | 43 (86)                       |                 |

*Chi square test
group, suggesting a statistically significant inter-group difference by independent t-test (P<0.001). In other words, according to Mann-Whitney’s test, symptoms had subsided in 78% of the patients in the oral metronidazole plus Prangos ferulacea vaginal cream group and 38% of those in the oral metronidazole group by the third day, suggesting a statistically significant inter-group difference (P<0.001) (Figure 2).

The frequency distribution of the day of full recovery over the seven days of treatment showed that 78% of the patients in the oral metronidazole plus Prangos ferulacea vaginal cream group and 30% of those in the oral metronidazole group fully recovered by the end of the fourth day, suggesting a statistically significant inter-group difference (P<0.004) (Figure 3).

Examining the medication side-effects showed that none of the patients in either of the two groups experienced sensitivity to light, diarrhea, vomiting, vaginal bleeding, pelvic pain and vaginal or vulvar itching, burning, and inflammation. A total of 16% of the patients in the Prangos ferulacea group and 24% of those in the metronidazole group experienced medication side-effects (nausea, metallic taste and stomach ache), with metallic taste and nausea being the most frequent side-effects in both groups; none of the patients in the Prangos ferulacea group had stomach ache. The Chi-square test showed no significant differences between the

| Variable                  | Intervention group N (%) | Control Group N (%) | P value* Before treatment | P value* After treatment |
|---------------------------|--------------------------|---------------------|---------------------------|--------------------------|
| Patient complaints        | 49 (98)                  | 48 (96)             | <0.001                    | 8 (16)                   |
| Amsel clinical criteria   | 46 (92)                  | 46 (92)             | <0.001                    | 8 (16)                   |
| Microscopic criteria Nugent | 50 (100)                | 50 (100)            | <0.001                    | 6 (12)                   |

*McNemar’s test

Figure 2: Distribution of the participants according to the day when the symptoms of bacterial vaginosis (patient self-report) reduced in the control and intervention groups
two groups in terms of the side-effects of the medications (Figure 4).

**DISCUSSION**

The present findings showed the high efficacy of oral metronidazole plus Prangos ferulacea vaginal cream and oral metronidazole alone. After receiving the treatments, the homogeneous discharge reduced in the two groups. None of the patients in the oral metronidazole plus Prangos ferulacea vaginal cream group had a bad odor after treatment. Bad odor is one of the main features of bacterial vaginosis that is caused by polyamine metabolism in the bacteria, which is evaporated by the vaginal discharge. The response to treatment based on Amsel’s clinical and Nugent microscopic criteria was similar in both groups. No serious medication side-effects were observed in any of the groups.

A study compared the administration of oral metronidazole alone and oral metronidazole plus probiotic; it was reported that the response to treatment in the metronidazole alone group was better than that in the metronidazole plus probiotic group, suggesting no significant intergroup differences. Nonetheless, the rate of the recurrence of the disease two weeks after the treatment was almost similar in both groups and the side-effects were also negligible in both.20

Metronidazole is an antiprotozoal
nitroimidazole with an unclear mechanism of effect, but it is the gold standard of treatment for bacterial vaginosis\textsuperscript{11, 12} and has a strong antimicrobial activity against anaerobes.\textsuperscript{2}

The most common systemic side-effects of oral metronidazole include gastrointestinal complications, including nausea, vomiting, loss of appetite, diarrhea, abdominal cramps, constipation and tongue and mouth inflammation.\textsuperscript{11} The lengthy course of treatment with metronidazole can sometimes cause rapid changes in the human microbiota flora due to the high level of antibiotics administered. Intermittent preventive treatment is recommended for preventing the rapid reappearance of BV after discontinuation of the treatment.\textsuperscript{9}

In a study, the efficacy of long-term treatment was less than expected and the subjects developed significant bacterial resistance.\textsuperscript{21} Despite these treatments, the rate of recurrence of BV was very high and the medications administered had many side-effects.\textsuperscript{22} One study showed that the combination of routine antibiotics with natural antibiotics improved the treatment of bacterial vaginosis, especially in cases of microbial resistance.\textsuperscript{23}

Iran has a long history of using traditional medicine and medicinal plants for the treatment of different conditions. Herbal medicines are either effective or ineffective; their side-effects should, therefore, be carefully monitored. When a drug is effective, it must have some side-effects.\textsuperscript{13} According to the present findings and the results of the discussed studies regarding the side-effects of oral or topical metronidazole, Prangos ferulacea vaginal cream appears to have no additional side-effects over metronidazole while accelerating full recovery compared to the use of oral metronidazole in the treatment of BV.

The review of literature showed the lack of clinical trials performed in Iran or abroad on the use of Prangos ferulacea on humans although its medicinal properties have been proved in-vitro. Aluminum, iron, potassium, manganese, sodium, phosphorus, and zinc are the main minerals contained in the Prangos ferulacea plant.\textsuperscript{24} Prangos ferulacea is a rich source of antioxidants, and its antioxidant and protective effects are reportedly higher than those of vitamin E. in traditional medicine.\textsuperscript{25}

Moreover, the presence of phenolic compounds in Prangos ferulacea confirms its high antioxidant properties. The medicinal properties of Prangos ferulacea are due to the presence of Monoterin, Sescoueeterin, Coumarin, Flavondeid, Tannin, Salpounin, and Alkaloid.\textsuperscript{14}

The antimicrobial properties of the essence of this plant work against gram-positive Staphylococcus epidermidis, Staphylococcus aureus, gram-negative Salmonella typhi, shigella, and E. coli. Nonetheless, this plant has moderate antimicrobial effects on Staph saprophyticus.\textsuperscript{26} In addition to these properties, the flower of Prangos ferulacea has also been found to be effective on coccus bacillus and its leaves are effective on rod-shaped gram-negative bacteria.\textsuperscript{17} The antibacterial properties of this plant are probably due to the enzymatic inhibition of oxidized compounds or reaction with sulfhydryl groups.\textsuperscript{27}

One of the strengths of this study was the use of the Nugent method as a standard golden method for the diagnosis and treatment of vaginosis, and its innovation in the field of antibacterial effect of Prangos ferulacea gum in humans, according to researchers. This study is the first study done on humans. However, it also had limitations, including failure to follow up patients with recurrence of the disease and the use of oral metronidazole in both treatment groups. The results showed that the treatment group improved faster than the control group, but as to the use of Prangos ferulacea, as an alternative medicine, more studies are recommended to be conducted.

**Conclusion**

Prangos ferulacea or Prangos ferulacea vaginal cream accelerated the recovery of bacterial vaginosis of patients with bacterial
vaginosis based on Amsel’s clinical criteria, the Nugent microscopic criteria and the patients’ reduced complaints. Thus, it can be used as an effective complementary treatment with oral metronidazole in cases of medication resistance and also in people wishing to use herbal remedies. Nonetheless, further studies are required before it can be adopted as a common treatment without metronidazole.

**ACKNOWLEDGEMENT**

This article was extracted from master thesis of Asieh Azadpour Motlagh with the code no of 8192, which was supported by Shahid Beheshti University of Medical Sciences. The authors would like to express their appreciation to the participants.

**Conflict of Interest:** None declared.

**REFERENCES**

1. Gupta PS, Soni M, Sharma A. Vaginal Infections: A Common Gynecologic Disorder. International Journal of Health Sciences and Research (IJHSR). 2016;6:293-6.
2. Berek JS, Novak E. Berek and Novak’s Gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
3. Li XD, Tong F, Zhang XJ, et al. Incidence and risk factors of bacterial vaginosis among pregnant women: a prospective study in Maanshan city, Anhui Province, China. Journal of Obstetrics and Gynaecology Research. 2015;41:1214-22.
4. Hoffmann JN, You HM, Hedberg EC, et al. Prevalence of bacterial vaginosis and candida among postmenopausal women in the United States. J Gerontontology B Psychol Sci Soc Sci. 2014;69:S205-S14.
5. Mendling W. Vaginal Microbiota. In: Andreas Schwierz. Microbiota of the Human Body. Switzerland: Springer; 2016. p. 83-93.
6. Bafghi AF, Hoseinzadeh A, Jouzsheri MN, Mohseni P. Frequency and Etiology of Vaginitis in Women Referred to Health Centers in Yazd city. Int J Cur Microbiol App Sci. 2015;4:561-71.
7. Amini B, Baghchesaraie H, Torabi Z. Prevalence of bacterial vaginosis and impact of genital hygiene practices in non-pregnant women in Zanjan, Iran. Oman Medical Journal. 2009;24:288-93.
8. Ghiasi M, Fazaeli H, Kalhorn N, et al. Assessing the prevalence of bacterial vaginosis among infertile women of Qom city. Iranian Journal of Microbiology. 2014;6:404-8.
9. Mayer BT, Srinivasan S, Fiedler TL, et al. Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis. Journal of Infectious Diseases. 2015;212:793-802.
10. Homayouni A, Bastani P, Ziyadi S, et al. Effects of Probiotics on the Recurrence of Bacterial Vaginosis: A Review. Journal of Lower Genital Tract Disease. 2014;18:79-86.
11. Mahon C, Lehman D, Manuselis G. Textbook of diagnostic microbiology, 5th ed. Netherlands: Elsevier, Health Sciences Division; 2015.
12. Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
13. Nasri H, Shirzad H. Toxicity and safety of medicinal plants. Journal of HerbMed Pharmacology. 2013:2:21-2.
14. Kafash-Farkhad N, Asadi-Samani M, Rafieian-Kopaei M. A review on phytochemistry and pharmacological effects of Prangos ferulacea (L.) Lindl. Life Science Journal. 2013;10:360-7.
15. Avicenna. The Canon of Medicine (al-Qānūn Fi’l-ṭibb). 1st ed. Virginia: Great Books of the Islamic World; 1999.
16. Zargaran A, Zarshenas MM, Karimi A, et al. Management of stroke as described by Ibn Sina (Avicenna) in the Canon of Medicine. International Journal of Cardiology. 2013;169:233-7.
17. Sagun E, Durmaz H, Tarakci Z, Sagdic O.
Antibacterial activities of the extracts of some herbs used in Turkish herby cheese against Listeria monocytogenes serovars. International Journal of Food Properties. 2006;9:255-60.

18 Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations. American Journal of Medicine. 1983;74:14-22.

19 Damke SS, Fule RP, Tankhiwale NS. Utility of Ph and whiff test for screening of abnormal vaginal discharge among women of reproductive age in rural area. International Journal of Current Research and Review. 2016;8:33.

20 Lim MLR, Lasala L. Effectiveness and safety of metronidazole plus probiotics versus metronidazole alone in the treatment of bacterial vaginosis: randomized controlled trial. SPMC Journal of Health Care Services. 2015;1:31-7.

21 Schwebke JR, Marrazzo J, Beelen AP, Sobel JD. A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. Sex Transm Dis. 2015;42:376-81.

22 Alves P, Castro J, Sousa C, et al. Gardnerella vaginalis outcompetes 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in vitro biofilm formation model. Journal of Infectious Diseases. 2014;210:593-6.

23 Algburi A, Volski A, Chikindas ML. Natural antimicrobials subtilosin and lauramide arginine ethyl ester synergize with conventional antibiotics clindamycin and metronidazole against biofilms of Gardnerella vaginalis but not against biofilms of healthy vaginal lactobacilli. Pathogens and Disease. 2015;73(5).

24 Özcan MM, Dursun N, Arslan D. Some nutritional properties of Prangos ferulacea (L.) Lindl and Rheum ribes L. stems growing wild in Turkey. International Journal of Food Sciences and Nutrition. 2007;58:162-7.

25 Emamghoreishi M, Taghavi A, Javidnia K. The effect of aqueous and methanolic extracts of Prangos ferulaeae on formalin-induced pain in mice. Pars Journal of Medical Sciences. 2011;9:1-7.

26 Amiri H. Essential oil variation of Prangos ferulaeae Lindl. in different stage of plant growth. Iranian Journal of Medical and Aromatic Plants. 2007;23:121-7. [In Persian]

27 Razavi SM, Zahri S, Nazemiyeh H, et al. A furanocoumarin from Prangos uloptera roots, biological effects. Natural Product Research. 2009;23:1522-7.